Yüklüyor......
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
The understanding of the B cell receptor (BCR) pathway and its contribution to chronic lymphocytic leukemia (CLL) pathogenesis have led to the development of targeted BCR inhibitors which have transformed the treatment paradigm of CLL. Ibrutinib is a first-in-class oral Bruton’s tyrosine kinase (BTK...
Kaydedildi:
| Yayımlandı: | Drug Des Devel Ther |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7936706/ https://ncbi.nlm.nih.gov/pubmed/33688166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S250823 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|